Presented by Julia Malkowski, ND, DC | April 1, 2026 at 12 PM Pacific

Methylation is a fundamental biochemical process with far-reaching implications for human health. This presentation will offer an in-depth exploration of methylation, its clinical significance, and the impact of methylation imbalances on health outcomes.

Methylation is involved in cardiovascular health, detoxification, neurotransmitter synthesis, hormone metabolism, DNA expression, immune modulation and fetal development. Analyzing key methylation biomarkers provides valuable insight into human physiology. Plasma levels of methionine, s-Adenosyl methionine (SAM), s-Adenosyl homocysteine (SAH), homocysteine, cystathionine and cysteine provide a functional assessment of the methylation cycle. Attendees will walk away with an understating of these biomarkers, enhanced understanding of methylation dynamics and their impact on clinical outcomes.

Learning Objectives:

• Understand the role of methylation in human physiology
• Comprehend objective biomarkers of the methylation cycle, including the methylation ratio, methionine, SAM, SAH, homocysteine, cystathionine and cysteine
• Explore the clinical significance of methylation imbalances
• Discuss case applications and therapeutic strategies based on methylation status

Presented by Jeannie Gorman, MS, CCN | May 6, 2026 at 12 PM Pacific

This webinar will explore how the GI360™ provides a comprehensive view of the microbiome and dysbiosis, with insights into GLP-1 signaling pathways. Learn practical applications for patients with GI, autoimmune, cardiovascular, neurological, or skin conditions, and discover how stool insights can guide better clinical outcomes.

Learning Objectives:

• Describe the GI360™ complimentary methodologies and applications
• Identify patients who benefit from stool testing
• Interpret markers of dysbiosis and GLP-1-modulating bacteria
• Apply targeted probiotics, soluble fiber, diet, and dysbiosis therapies to support microbiome health and GLP-1 signal pathways
• Explain the role of retesting for optimizing microbiome and GLP-1-related outcomes